Neuropathy Alnylam's Onpattro OK'd in Canada for hATTRSeeking Alpha - Douglas W. House Alnylam Pharmaceuticals (ALNY -0.1%) announces Health Canada approval and the immediate availability of ONPATTRO (patisiran) for the treatment of …
Stocks Advaxis prices equity offering; shares down 27%Seeking Alpha - Douglas W. House Thinly traded nano cap Advaxis (ADXS -27%) is down on almost a 7x surge in volume in response to its public offering of 9.2M common shares, common …
Stocks RedHill inks $60M ADS sales deal with Leerink; shares down 10%Seeking Alpha - Douglas W. House Thinly traded RedHill Biopharma (RDHL -9.6%) is down on average volume, albeit on turnover of only 62K shares, on the heels of its agreement with SVB …
FlipboardIcon version of the Flipboard logo Joyn Bio and NewLeaf Symbiotics Join Forces in $75M Dealprnewswire.com CHICAGO, July 22, 2019 /PRNewswire/ -- Today, at AgTech Nexus USA, NewLeaf Symbiotics and Joyn Bio announced a long-term partnership valued at up to …
Could a ‘Bio-Belt’ Boost the Economy of Rural America?biospace.com Could biotech be the catalyst for a financial boom in the heartland of America? For John Cumbers, chief executive officer of SynBioBeta, an innovation …
Reckitt Benckiser One opioid drugmaker's solution to billions of potential liabilities: spin them out into new companyCNBC - Meg Tirrell Facing the prospect of millions, or even billions, of dollars in potential liabilities tied to the nation's opioid epidemic, one drugmaker has a …
Fingerprint of multiple sclerosis immune cells identifiedmedicalxpress.com - Science X staff Researchers at the University of Zurich have identified a cell population that likely plays a key role in multiple sclerosis (MS). T helper cells in …
Biogen Multiple sclerosis drug helps Biogen beat Wall St. profit expectationsReuters - By Saumya Joseph and Manas Mishra(Reuters) - Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera
Business Acadia stock drops as schizophrenia drug doesn't pass clinical trialMarketWatch - By Wallace Witkowski Acadia Pharmaceuticals Inc. ACAD, +1.05% shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment …
FDA FDA OKs expanded population for Lipocine's NASH candidate LPCN 1144Seeking Alpha - Douglas W. House Lipocine (NASDAQ:LPCN) announces that the FDA has signed off on expanding the target population of adult male NASH patients for LPCN …
Nasdaq Sell-siders bullish on Karuna Therapeutics in premarket actionSeeking Alpha - Douglas W. House Karuna Therapeutics (NASDAQ:KRTX) initiated with Buy rating and $28 (42% upside) price target at Citigroup. Initiated with Buy rating and $34 price …
Investing Amarin: Valuations Are Still Attractive, This Biotech Stock Is Set To FlySeeking Alpha - Value Kicker When building out a diversified portfolio to beat the market (I mean the website is called Seeking Alpha, not Seeking Beta), it is useful to add a …
Investing Menlo Therapeutics And Serlopitant In Dermal PruritusSeeking Alpha - First Genesis Consulting Menlo Therapeutics (MNLO) is a small-cap ($103M) clinical-stage biopharmaceutical company developing innovative drug candidates therapeutically …
Investing Corvus Pharmaceuticals: Attractive Entry LevelSeeking Alpha - PylBio Investment Today, we want to share our analysis of Corvus Pharmaceuticals (NASDAQ:CRVS) with you. Over the last year, its stock largely fluctuated, falling from …
Biogen Biogen Q2 revenues up 8%; earnings up 72%Seeking Alpha - Douglas W. House Net income: 1,494 (+72.3%); non-GAAP net income: 1,742 (+44.9%); EPS: 7.85 (+87.8%); non-EPS: 9.15 (+57.8%). Key product sales: Tecfidera: 1,150 …
Biogen Ionis down 6% after Biogen posts Q2 Spinraza salesSeeking Alpha - Douglas W. House Ionis Pharmaceuticals (NASDAQ:IONS) slips 6% premarket on light volume following licensee Biogen's Q2 report that included a relatively modest 15% …
Placebos Chiasma's Mycapssa successful in late-stage acromegaly study; shares up 30% premarketSeeking Alpha - Douglas W. House Thinly traded micro cap Chiasma (NASDAQ:CHMA) is up 30% premarket on increased volume in response to positive results from a Phase 3 clinical trial, …
Myovant's relugolix successful in late-stage study; shares up 9% premarketSeeking Alpha - Douglas W. House Thinly traded Myovant Sciences (NYSE:MYOV) is up 9% premarket on light volume following its announcement of positive results from a second Phase 3 …
Placebos Marinus down 68% premarket on disappointing ganaxolone dataSeeking Alpha - Douglas W. House Marinus Pharmaceuticals (NASDAQ:MRNS) plummets 68% premarket on increased volume in response to results from the second part of a Phase 2 clinical …
JPMorgan Chase Karyopharm up 8% premarket on JPMorgan upgradeSeeking Alpha - Douglas W. House Karyopharm Therapeutics (NASDAQ:KPTI) is up 8% premarket on light volume on the heels of an upgrade to Overweight with a $16 (92% upside) price …
Investing Drug Pricing Reform Shifts CourseSeeking Alpha - Janus Henderson Investors By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare …
Investing Amarin: Hitting A New Inflection PointSeeking Alpha - BioSci Capital Partners History has shown that in every age and in every field of human knowledge, many of the views which almost everyone accepted as true and never …
Investing What Happens If Pacific Biosciences Isn't Acquired By Illumina?The Motley Fool - Maxx Chatsko Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors. A nervous energy …
Radiation Adaptimmune up 10% on promise of low-dose radiation to improve SPEAR T-cell therapySeeking Alpha - Douglas W. House Thinly traded micro cap Adaptimmune Therapeutics plc (ADAP +10.4%) is up on modestly higher volume, albeit on turnover of only 306K shares, in …
Investing Annovis Bio Begins U.S. IPO EffortSeeking Alpha - Donovan Jones Annovis Bio (OTC:ANVS) has filed to raise gross proceeds of up to $11.5 million from a U.S. IPO, according to an S-1 registration statement. The firm …
Pfizer ViiV's fostemsavir shows long-term benefit in treatment-experienced HIV patientsSeeking Alpha - Douglas W. House Results from a Phase 3 clinical trial, BRIGHTE, evaluating ViiV Healthcare's fostemsavir in heavily pretreated HIV patients showed a treatment …
Stocks Hemispherx down 21% on stock sales dealSeeking Alpha - Douglas W. House Thinly traded nano cap Hemispherx Biopharma (HEB -20.5%) is down on 40% higher volume, albeit on turnover of only 272K shares, in apparent response …
ContraVir Pharmaceuticals changes name to Hepion Pharmaceuticals; trading symbol change to “HEPA”Seeking Alpha - Akanksha Bakshi ContraVir Pharmaceuticals (CTRV +1.7%) announced that its Board of Directors approved the change of the Company’s name and stock symbol to Hepion …
Investing Assessing An Investment In Myovant SciencesSeeking Alpha - Busted IPO Forum I regard golf as an expensive way of playing marbles." - G.K. Chesterton Being in London this week, I thought today, we would take an in-depth look at …
